Ortho Micronor Articles
Warner Chilcott and Barr settle Femcon dispute
12 January 2009
US FTC settles with Barr Labs over Ovcon
10 December 2007
FDA clears Barr's generic Estrostep
5 November 2007
Watson files for generic Femcon
8 October 2007
Public Citizen calls for US FDA to ban third-gen oral contraceptives
12 February 2007
Watson launches Warner Chilcott's Zenchent
5 February 2007
First chewable birth control pill
11 December 2006
Generic drug antitrust settlement with US FTC
6 November 2006
Warner Chilcott's 2nd-qtr losses fall 34.8%
28 August 2006
Warner Chilcott files patent suit over Loestrin 24 Fe
7 August 2006
New Warner Chilcott posts 1st-qtr loss
11 July 2005
Warner Chilcott's low-dose femhrt approved
24 January 2005
Battle for Warner Chilcott may continue
8 November 2004
UPDATE: Ireland's Warner Chillcott mulls L1.7 billion offer from private equity group
27 September 2004
Warner Chilcott beats expectations
16 August 2004
Galen sees 2nd-qtr 2004 EPS rocket 84%
24 May 2004
Barr and Galen announce Loestrin and Ovcon 35 deals
5 April 2004
Novo Nordisk enrolls Innovex for menopause drugs sales
29 March 2004
Galen reports 105% leap in 1st-qtr sales
16 February 2004
Galen gains US exclusivity period for Ovcon
26 January 2004
FDA approves new Ovcon 35
24 November 2003
Barr Labs and Galen in oral contraceptives licensing deal
22 September 2003
Stock Commentary - Europe
18 August 2003
Barr completes deal to acquire Wyeth prods
16 June 2003
Pfizer tries to end Novo HRT deal
9 June 2003
Galen completes Pfizer product acquisitions
28 April 2003
Watson launches Microgestin OC in USA
14 April 2003
Galen seeking to buy Pfizer drugs for $359M
10 March 2003
Galen EPS leaps 35%, beating forecasts
17 February 2003
Noven Pharma boost from JV revenues
4 March 2002
Pretax profits up 25% at Novo Nordisk
18 February 2002
Pretax profits up 33% at Novo Nordisk
7 November 2001
Canada accuses GSK, Roche of tax dodging
10 July 2001
Galen 2nd-qtr profits and revenues soar
2 May 2001
Tentative approval for Barr's generic contraceptive
15 March 2001
Novo Nordisk and AHP settle HRT litigation
21 June 2000
Novo Nordisk and AHP settle patent dispute
16 June 2000
Barr mounts challenge to Ortho contraceptive in USA
15 June 2000
Pharmacia gains FDA OK for Activella
18 April 2000
Warner Chilcott acquires women's products from B-MS
28 January 2000
P&U to market Novo Nordisk's HRT drugs in USA
13 January 2000
US FDA Approves Novo Nordisk's Activelle
19 November 1998
First Combination HRT Patch Cleared In USA
13 August 1998
W-L To Stay Independent As Product Line Improves
30 April 1998
W-L To Stay Independent As Product Line Improves
24 April 1998
Warner-Lambert Launches Estrostep In USA
7 April 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Parke-Davis's Estrostep Approved In USA
21 October 1996
Wyeth-Ayerst To Take Annuelle Into Ph III
26 September 1994
CYGNUS TO FILE FOR ALPRAZOLAM PATCH
23 August 1993
ROBERTS PRODUCT UPDATE
18 January 1993
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
Showing 1-58 of 58 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
